Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company?s lead product candidate, ADS-5102, is being developed for a complication of Parkinson?s disease, known as levodopa-induced dyskinesia, and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. Its portfolio also includes an NDA-submitted fixed-dose combination product candidate, MDX-8704, which is being co-developed with Forest Laboratories, Inc.; and an approved controlled-release product, Namenda XR. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-2.84||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-99.1%||Sales Growth - Q/Q||-99.25%||P/E||-6.16|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||2.99%||ROE||3.2%||ROI|
|Current Ratio||14.25||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.06|
|Gross Margin||Operating Margin||21.43%||Net Profit Margin||7.87%||Dividend Payout Ratio|
|Cash From Financing Activities||300 K||Cash From Investing Activities||-18.45 M||Cash From Operating Activities||-14.06 M||Gross Profit|
|Net Profit||-12.2 M||Operating Profit||-12.23 M||Total Assets||147.34 M||Total Current Assets||115.52 M|
|Total Current Liabilities||8.11 M||Total Debt||Total Liabilities||9.79 M||Total Revenue||230 K|
|High 52 week||42.65||Low 52 week||5.48||Last close||5.73||Last change||-3.86%|
|RSI||31.77||Average true range||0.3||Beta||1.57||Volume||92.31 K|
|Simple moving average 20 days||-5.84%||Simple moving average 50 days||-15.11%||Simple moving average 200 days||-74%|
|Performance Week||2.32%||Performance Month||-10.47%||Performance Quart||-76.34%||Performance Half||-81.62%|
|Performance Year||-79.54%||Performance Year-to-date||-75.52%||Volatility daily||2.42%||Volatility weekly||5.41%|
|Volatility monthly||11.1%||Volatility yearly||38.44%||Relative Volume||208.74%||Average Volume||562.75 K|
|New High||New Low|
2019-12-12 00:20:00 | NOTICE FROM THE FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-12-11 22:00:00 | NOTICE FROM THE FILING LAW FIRM: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-12-11 16:16:00 | IMPORTANT INVESTOR ALERT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-12-09 16:50:40 | Adamas Announces New Employment Inducement Grant
2019-12-06 14:45:00 | INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-12-05 09:28:02 | Implied Volatility Surging for Adamas Pharmaceuticals ADMS Stock Options
2019-11-21 16:02:00 | Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences
2019-11-19 10:58:25 | Edited Transcript of ADMS earnings conference call or presentation 7-Nov-19 9:30pm GMT
2019-11-08 16:01:00 | Adamas Announces New Employment Inducement Grant
2019-11-07 18:55:11 | Adamas Pharmaceuticals ADMS Reports Q3 Loss, Lags Revenue Estimates
2019-11-07 16:03:00 | Adamas Reports Third Quarter 2019 Financial Results
2019-11-04 11:01:04 | What's in the Offing for Humana's HUM Earnings in Q3?
2019-10-08 16:03:00 | Adamas Announces New Employment Inducement Grant
2019-09-27 16:05:00 | Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference
2019-09-17 16:15:00 | Adamas Announces New Employment Inducement Grant
2019-09-13 07:30:00 | Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer
2019-09-10 16:15:00 | Adamas Announces New Employment Inducement Grant
2019-08-12 17:07:38 | Adamas Announces New Employment Inducement Grant
2019-08-12 03:11:24 | Adamas Pharmaceuticals Inc ADMS Q2 2019 Earnings Call Transcript
2019-08-09 13:33:50 | Edited Transcript of ADMS earnings conference call or presentation 8-Aug-19 8:30pm GMT
2019-08-08 16:02:00 | Adamas Reports Second Quarter 2019 Financial Results
2019-08-08 11:11:09 | Need To Know: Adamas Pharmaceuticals, Inc. NASDAQ:ADMS Insiders Have Been Selling Shares
2019-07-29 09:43:01 | What's in Store for DENTSPLY SIRONA XRAY in Q2 Earnings?
2019-07-08 16:29:28 | Adamas Announces New Employment Inducement Grant
2019-07-08 09:24:01 | Top Ranked Momentum Stocks to Buy for July 8th
2019-07-05 08:35:12 | Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
2019-06-28 20:37:54 | Hedge Funds Are Dumping Adamas Pharmaceuticals Inc ADMS
2019-06-27 12:00:00 | Lifshitz & Miller LLP Announces Investigation of Adamas Pharmaceuticals, Inc., ASGN Incorporated, Box, Inc., ChinaCache International Holdings Ltd, Mammoth Energy Services, Inc., Realogy Holdings Corp., Total System Services, Inc., and Verint Systems Inc.
2019-06-25 08:10:12 | Will Adamas Pharmaceuticals Continue to Surge Higher?
2019-06-21 10:37:02 | Bausch Health BHC Catches Eye: Stock Jumps 6.2%
2019-06-20 09:56:48 | Should You Worry About Adamas Pharmaceuticals, Inc.'s NASDAQ:ADMS CEO Salary Level?
2019-06-20 09:51:01 | Allergan AGN in Focus: Stock Moves 6.2% Higher